BioCryst Pharmaceuticals, Inc. Financials

Market Capitalization $1.87 Billion as of July 1, 2025

Valuations Metrics as of Jul. 5, 2025

Trailing PE	-20.79
Forward PE	-223.50
Price to Sales TTM	$3.72
Price to Book MRQ	$-4.13
Enterprise to Revenue	4.79
Enterprise to EBITDA	64.29

Financial Reports as of Mar. 31, 2025

Financials

Fiscal Year Ends	2024-12-31
Most Recent Quarter	2025-03-31
Profit Margin	-10.62%
Operating Margin	14.59%
Return on Assets TTM	4.54%
Return on Equity TTM	18.68%

Income Statement

Revenue TTM	$503,484,992
Revenue per Share TTM	$2.43
Quarterly Revenue Growth	56.90%
Gross Profit TTM	$323,483,008
EBITDA	$13,449,000
Net Income to Common TTM	$-53,470,000
Diluted EPS TTM	$-0.26
Quarterly Earnings Growth YoY	56.89%

Balance Sheet

Total Cash MRQ	$295,092,000
Total Cash per Share MRQ	$1.41
Total Debt MRQ	$
Total Debt to Equity MRQ	-1.84
Current Ratio MRQ	2.93
Book Value per Share MRQ	$-2.16

Cash Flow

Operating Cash Flow TTM	$-25,853,000
Levered Free Cash Flow TTM	$42,902,500

BCRX Stock Info as of Jul. 5, 2025

Stock Statistics

Shares Outstanding	208,543,452
Float Shares	207,019,666
Avg 10 Volume	3,867,130
Avg 30 Volume	None
Shares Short	23,076,302
Short Ratio	5.52
Short % of Shares	11.07%
% Held by Insiders	1.20%
% Held by Institutions	85.56%

Stock Price Summary

Beta	1.10
Fifty Two Week Low	$6.02
Fifty Two Week High	$11.31
Fifty Two Week Change	28.19%
Day 50 MA	$9.96
Day 200 MA	$8.30

Dividends and Splits

Forward Annual Dividend Rate	$
Forward Annual Dividend Yield	%
Trailing Annual Dividend Rate	$0.00
Trailing Annual Dividend Yield	0.00%
Payout Ratio	0.00%
Dividend Date
Ex Dividend Date	2014-06-11
Last Split Factor
Last Split Date